European Commission expands approval for teclistamab monotherapy in relapsed/refractory multiple myeloma

The European Commission (EC) has approved an extension of the indication for teclistamab (Tecvayli) monotherapy to include adult patients with relapsed/refractory multiple myeloma who have received at least one prior therapy. This expands on its initial approval in August 2022, which was for patients who had received at least three prior therapies, offering an additional immunotherapy option earlier in the treatment pathway.